Low- or standard-dose edoxaban versus antiplatelet therapy for leaflet thrombus and cerebral thromboembolism after TAVR: A prespecified analysis of randomized ADAPT-TAVR trial
Journal
American heart journal
Journal Volume
269
Pages
167-178
Date Issued
2024-03
Author(s)
Kim, Mijin
Ahn, Jung-Min
Kang, Do-Yoon
Kim, Min-Ju
Kim, Kyung Won
Koo, Hyun Jung
Yang, Dong Hyun
Jung, Seung Chai
Kim, Byungjun
Wong, Yiu Tung Anthony
Lam, Cheung Chi Simon
Yin, Wei-Hsian
Wei Jeng
Lee, Yung-Tsai
Yu Ko, Tsung
Kim, Won-Jang
Kang, Se Hun
Lee, Seung-Ah
Ko, Euihong
Kim, Dae-Hee
Kang, Joon-Won
Lee, Jae-Hong
Lee, Jinho
Park, Jinsun
Kim, Hoyun
Choi, Yeonwoo
Park, Seung-Jung
Park, Duk-Woo
Abstract
The risks of leaflet thrombosis and the associated cerebral thromboembolism are unknown according to different anticoagulation dosing after transcatheter aortic valve replacement (TAVR). The aim was to evaluate the incidence of leaflet thrombosis and cerebral thromboembolism between low-dose (30 mg) or standard-dose (60 mg) edoxaban and dual antiplatelet therapy (DAPT) after TAVR.
Type
journal article